Pitfalls in mutational testing and reporting of common KIT and PDGFRA mutations in gastrointestinal stromal tumors
Authors:
- Sabine Merkelbach-BruseSMSabine Merkelbach-Bruse
- Wolfgang DietmaierWDWolfgang Dietmaier
- Laszlo FüzesiLFLaszlo Füzesi
- Andreas GaumannAGAndreas Gaumann
- Florian HallerFHFlorian Haller
- Julia KitzJKJulia Kitz
- Antje KrohnAKAntje Krohn
- Gunhild MechtersheimerGMGunhild Mechtersheimer
- Roland PenzelRPRoland Penzel
- Hans-Ulrich SchildhausHSHans-Ulrich Schildhaus
- Regine Schneider-StockRSRegine Schneider-Stock
- Ronald SimonRSRonald Simon
Open Access
- 4 July 2010
- journal article
- Published by Springer Nature in BMC Medical Genetics
- Vol. 11 (1) , 106
Abstract
Mutation analysis of KIT and PDGFRA genes in gastrointestinal stromal tumors is gaining increasing importance for prognosis of GISTs and for prediction of treatment response. Several groups have identified specific mutational subtypes in KIT exon 11 associated with an increased risk of metastatic disease whereas GISTs with PDGFRA mutations often behave less aggressive. Furthermore, in advanced GIST disease with proven KIT exon 9 mutation the doubled daily dose of 800 mg imatinib increases the progression free survival and is now recommended both in the European and the American Guidelines. In Germany, there are still no general rules how to perform mutational analysis.Keywords
This publication has 31 references indexed in Scilit:
- Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST)European Journal of Surgical Oncology, 2009
- Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology GroupJournal of Clinical Oncology, 2008
- Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, a Heat Shock Protein 90 Inhibitor, against Gastrointestinal Stromal Tumor–Associated PDGFRAD842V MutationClinical Cancer Research, 2008
- The role of adjuvant and neoadjuvant therapy in gastrointestinal stromal tumorsCurrent Opinion in Oncology, 2008
- KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumoursEuropean Journal of Cancer, 2006
- Detection of a new mutation in KIT exon 9 in a gastrointestinal stromal tumorInternational Journal of Cancer, 2005
- PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to ImatinibJournal of Clinical Oncology, 2005
- Clinical and molecular characteristics of pediatric gastrointestinal stromal tumors (GISTs)Pediatric Blood & Cancer, 2005
- Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal TumorJournal of Clinical Oncology, 2003
- Sample preparation and PCR amplification from paraffin-embedded tissues.Genome Research, 1994